...
首页> 外文期刊>Analytical methods >Microcapsules as assay compartments formed through layer-by-layer deposition
【24h】

Microcapsules as assay compartments formed through layer-by-layer deposition

机译:通过逐层沉积形成的微胶囊作为化验室

获取原文
           

摘要

We investigate the potential of using microcapsules, generated through layer-by-layer assembly, as reaction compartments for bioassays. A streptavidin–biotin and an esterase-fluorescein diacetate (FDA) assay were employed for proof-of-concept. Streptavidin was incorporated into the microcapsules via two methods: (i) physical adsorption onto MnCO3 microcrystal templates or (ii) co-precipitation with CaCO3 to form mixed microcrystals. The streptavidin-loaded template microparticles were then coated with five bi-layers of polyelectrolytes (polyallylamine hydrochloride/polystyrene sulfonate) (PAH/PSS)5 and the templated cores were dissolved using EDTA to form polyelectrolyte microcapsules loaded with streptavidin. Streptavidin loading of around 77 mg streptavidin per mol of CaCO3 was achieved using the co-precipitation method, compared to 5.1 mg streptavidin per mol of MnCO3 using physical adsorption onto the manganese carbonate crystal surface. The microencapsulated streptavidin was allowed to bind to an analyte which was able to freely diffuse through the polyelectrolyte shell from the aqueous media. Biotin-4-fluorescein was added to the streptavidin-loaded microcapsules, with streptavidin-free capsules serving as the control sample. It was found that both types of microcapsules exhibited a similar fluorescence signal intensity, likely due to non-specific binding of biotin-4-fluorescein to charged groups on the polyelectrolyte shell. Therefore, an alternative esterase-FDA assay was investigated as fluorescence is only produced when FDA penetrates the capsule shell and reacts with the esterase enzyme inside which leads to its hydrolysis. Esterase was loaded into the LbL capsules templated on CaCO3via co-precipitation. FDA was added to both the esterase-loaded capsules and esterase-free capsules. It was found that the capsules containing esterase fluoresced, while the esterase-free capsules did not. This indicates that the hydrolysis reaction of FDA with esterase occurred inside the LbL microcapsules. These experiments demonstrate the potential of compartmentalised assays to be carried out inside microcapsules which could be applied in complex matrices or in multiplexing experiments, wherein different barcoded microcapsules contain different reagents to provide independent readouts without interference from larger biomolecules present in the surrounding media.
机译:我们调查了使用通过逐层组装产生的微胶囊作为生物测定反应室的潜力。用链霉亲和素-生物素和酯酶-荧光素二乙酸酯(FDA)法进行概念验证。通过两种方法将链霉亲和素掺入微囊中:(i)物理吸附到MnCO3微晶模板上,或(ii)与CaCO3共沉淀以形成混合微晶。然后将负载链霉亲和素的模板微粒涂上五层双层聚电解质(聚烯丙胺盐酸盐/聚苯乙烯磺酸盐)(PAH / PSS)5,并使用EDTA将模板化的核心溶解,以形成负载链霉亲和素的聚电解质微胶囊。使用共沉淀法,链霉亲和素的负载量为每摩尔CaCO3约77 mg链霉亲和素,而使用物理吸附到碳酸锰晶体表面上的链霉亲和素为5.1毫克链霉亲和素/ mol MnCO3。使微囊化的抗生蛋白链菌素结合至能够从水性介质自由地扩散通过聚电解质壳的分析物。将生物素-4-荧光素添加到负载抗生蛋白链菌素的微胶囊中,将无抗生蛋白链菌素的胶囊用作对照样品。发现两种类型的微囊均表现出相似的荧光信号强度,这可能是由于生物素-4-荧光素与聚电解质壳上带电基团的非特异性结合。因此,研究了另一种酯酶-FDA分析方法,因为只有当FDA穿透胶囊壳并与内部的酯酶反应并产生水解时,才会产生荧光。通过共沉淀将酯酶加载到以CaCO3为模板的LbL胶囊中。将FDA添加到装有酯酶的胶囊和无酯酶的胶囊中。发现含有酯酶的胶囊发荧光,而不含酯酶的胶囊则发荧光。这表明FDA与酯酶的水解反应发生在LbL微胶囊内部。这些实验证明了在微胶囊内部进行区室化分析的潜力,可将其应用于复杂基质或多重实验中,其中不同条形码的微胶囊包含不同的试剂以提供独立的读数,而不受周围介质中存在的较大生物分子的干扰。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号